Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 10806702
    Abstract: The present invention provides bis-polymer lipid-peptide conjugates containing a hydrophobic block and headgroup containing a helical peptide and two polymer blocks. The conjugates can self-assemble to form helix bundle subunits, which in turn assemble to provide micellar nanocarriers for drug cargos and other agents. Particles containing the conjugates and methods for forming the particles are also disclosed.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: October 20, 2020
    Assignee: The Regents of the University of California
    Inventors: Ting Xu, He Dong, Jessica Shu, Nikhil Dube
  • Patent number: 10799563
    Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 13, 2020
    Assignee: Ascendis Pharma Endocrinology Division
    Inventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
  • Patent number: 10799562
    Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: October 13, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Steven K. Grinspoon
  • Patent number: 10787487
    Abstract: Presented herein are cyclic peptides that specifically bind to a cell surface molecule, thereby allowing cell/tissue-specific targeting. The cyclic peptides can be attached to an agent, for example, a polypeptide such as an antibody, e.g., a cell-penetrating antibody. Cyclic peptide-containing cell/tissue-specific cell-penetrating antibodies described herein are capable of targeted delivery in a cell type-specific or tissue-specific (i.e., cell/tissue-specific) manner. The cell/tissue-specific cell-penetrating antibodies described herein can be used as an effective anticancer agent for cancer that overexpresses a cell membrane protein that specifically binds to the fused cyclic peptides.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 29, 2020
    Assignee: ORUM THERAPEUTICS INC.
    Inventors: Yong Sung Kim, Ji Sun Kim, Jae Yeong Park, Seong Wook Park, Sei Yong Jun, Dong-Ki Choi
  • Patent number: 10787505
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: September 29, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10772931
    Abstract: Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 15, 2020
    Assignee: Purdue Research Foundation
    Inventors: Alyssa Panitch, Rebecca Scott
  • Patent number: 10765625
    Abstract: Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: September 8, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas Cox, Jennifer R. Cochran, Mark Smith, James R. Kintzing
  • Patent number: 10736880
    Abstract: Methods and compositions are provided for treating and preventing preterm labor using liposome encapsulated tocolytic agents, such as indomethacin. In certain aspects, targeted liposomes are provided that allow delivery of tocolytic agents directly to the uterus, such as by targeting to the oxytocin receptor.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 11, 2020
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS, THE METHODIST HOSPITAL
    Inventors: Jerrie S. Refuerzo, Biana Godin, Monica Longo
  • Patent number: 10738085
    Abstract: Disclosed herein are N-aminated variants of Gramicidin S and methods of using the same for treating infections in a subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 11, 2020
    Assignee: University of South Florida
    Inventors: Juan R. Del Valle, Lindsey Shaw
  • Patent number: 10738102
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: August 11, 2020
    Assignee: LIB THERAPEUTICS, LLC.
    Inventors: Tracy S. Mitchell, Richard Mealey
  • Patent number: 10730919
    Abstract: The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 4, 2020
    Assignee: APITOPE INTERNATIONAL NV
    Inventor: David Wraith
  • Patent number: 10730927
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 4, 2020
    Assignee: CSL LIMITED
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Patent number: 10730913
    Abstract: Disclosed herein are N-aminated variants of Gramicidin S and methods of using the same for treating infections in a subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 4, 2020
    Assignee: University of South Florida
    Inventors: Juan R. Del Valle, Lindsey Shaw
  • Patent number: 10725045
    Abstract: Methods are provided for treating a cancer patient suffering from a glioblastoma (GBM) by administering to the patient an effective amount of temozolomide, wherein a mass spectrometry analysis of a protein digest of a formalin-fixed tumor sample from the patient evidences an amount of a MGMT fragment peptide less than or substantially equal to 150 amol/?g.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Patent number: 10722531
    Abstract: Improved methods for treating cancer are provided herein by determining if a cancer patient, particularly a colon cancer patient or a gastric cancer patient, will clinically respond in a favorable manner to a therapeutic strategy comprising the FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin) or a combination of capecitabine and cisplatin. Diagnostic methods for measuring the OPRT, TYMP, and/or UCK2 proteins in a tissue sample, such as a tumor sample, from the patient are provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Patent number: 10722509
    Abstract: Methods are provided herein for identifying whether a cancer patient, for example a colorectal cancer patient, will be responsive to treatment with a therapeutic strategy comprising administration of the FOLFOX regimen (5-fluorouracil, leucovorin, and oxaliplatin). Specified TYMP and UCK2 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, for example colorectal cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the combination treatment of FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin).
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Fabiola Cecchi, Todd Hembrough
  • Patent number: 10718780
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the tyrosine-protein kinase receptor UFO protein (AXL) that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 21, 2020
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Todd Hembrough, Adele Blackler, Wei-Li Liao
  • Patent number: 10718779
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: July 21, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Patent number: 10711039
    Abstract: Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 14, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 10709757
    Abstract: The present invention relates to a composition for inhibiting angiogenesis, containing neo-N-methylsansalvamide (NMSSV), which is a cyclic pentadepsipeptide, as an effective ingredient, and specifically, since the NMSSV of the present invention has excellent activity which inhibits cell migration and tube formation associated with angiogenesis, and concentration-dependently inhibits angiogenesis induced by a vascular endothelial growth factor, it is expected that the NMSSV of the present invention may inhibit angiogenesis and be usefully used as a therapeutic agent for various diseases in which angiogenesis is abnormally regulated.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: July 14, 2020
    Assignee: CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Chan Lee, Sung-Kwon Moon, Jee Taek Kim